Literature DB >> 34261861

Emerging non-pharmacological interventions in ADPKD: an update on dietary advices for clinical practice.

Esther Meijer1, Ron T Gansevoort.   

Abstract

PURPOSE OF REVIEW: Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) reach kidney failure at a median age of 58 years. There has been a strong interest in medical interventions to improve prognosis. With increasing understanding of the underlying pathophysiology, there is also a rationale for non-pharmaceutical interventions. However, these have received little attention. This review, therefore, focuses on dietary interventions in ADPKD. RECENT
FINDINGS: Recent studies regarding salt, protein and water intake, caloric restriction, BMI, caffeine and alcohol are discussed in this review. In general, these studies suggest that advices do not need to be different from those in chronic kidney disease (CKD). On the basis of research in the general population and CKD, these advices will likely decrease cardiovascular morbidity and mortality. With respect to delaying ADPKD progression, evidence for salt restriction is growing. For increasing water intake and targeting glucose metabolism by intermittent fasting, preclinical studies are promising. Long-term randomized human intervention studies are, however, lacking.
SUMMARY: In ADPKD, advices regarding dietary interventions can, in general, be the same as in CKD to decrease cardiovascular morbidity and mortality. Whether these interventions also delay disease progression needs further study.
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34261861     DOI: 10.1097/MNH.0000000000000734

Source DB:  PubMed          Journal:  Curr Opin Nephrol Hypertens        ISSN: 1062-4821            Impact factor:   2.894


  1 in total

Review 1.  Drugs in Clinical Development to Treat Autosomal Dominant Polycystic Kidney Disease.

Authors:  Thomas Bais; Ron T Gansevoort; Esther Meijer
Journal:  Drugs       Date:  2022-07-19       Impact factor: 11.431

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.